ASKB589

· Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for ASKB589, covering 2025-09-10 to 2026-01-27. Get the full timeline:

Most recent: Clinical Trial Update: ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma [Phase 3]

See pricing